293 related articles for article (PubMed ID: 18759282)
21. Clinical characteristics of patients with vasculitis positive for anti-neutrophil cytoplasmic antibody targeting both proteinase 3 and myeloperoxidase: a retrospective study.
Kim SM; Choi SY; Kim SY; Kim J
Rheumatol Int; 2019 Nov; 39(11):1919-1926. PubMed ID: 31552433
[TBL] [Abstract][Full Text] [Related]
22. A retrospective study on the outcomes of MPO-ANCA-associated vasculitis in dialysis-dependent patients.
Hasegawa M; Hattori K; Sugiyama S; Asada H; Yamashita H; Takahashi K; Hayashi H; Koide S; Sato W; Yuzawa Y
Mod Rheumatol; 2016; 26(1):110-4. PubMed ID: 25967129
[TBL] [Abstract][Full Text] [Related]
23. ANCA positive crescentic glomerulonephritis outcome in a Central East European cohort: a retrospective study.
Andreiana I; Stancu S; Avram A; Taran L; Mircescu G
BMC Nephrol; 2015 Jun; 16():90. PubMed ID: 26123651
[TBL] [Abstract][Full Text] [Related]
24. Prevalence and risk factors of relapse in patients with ANCA-associated vasculitis receiving cyclophosphamide induction: a systematic review and meta-analysis of large observational studies.
He P; Hu JP; Tian XJ; He LJ; Sun SR; Huang C
Rheumatology (Oxford); 2021 Mar; 60(3):1067-1079. PubMed ID: 33677596
[TBL] [Abstract][Full Text] [Related]
25. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment.
Sanders JS; Huitma MG; Kallenberg CG; Stegeman CA
Rheumatology (Oxford); 2006 Jun; 45(6):724-9. PubMed ID: 16399845
[TBL] [Abstract][Full Text] [Related]
26. Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.
McGregor JG; Hogan SL; Kotzen ES; Poulton CJ; Hu Y; Negrete-Lopez R; Kidd JM; Katsanos SL; Bunch DO; Nachman PH; Falk RJ
Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1(Suppl 1):i123-31. PubMed ID: 25805743
[TBL] [Abstract][Full Text] [Related]
27. Maintenance of Remission and Risk of Relapse in Myeloperoxidase-Positive ANCA-Associated Vasculitis with Kidney Involvement.
Casal Moura M; Specks U; Tehranian S; Sethi S; Zubidat D; Nardelli L; Dos Santos FG; Sousa C; León-Róman J; Bobart SA; Greene E; Zand L; Fervenza FC
Clin J Am Soc Nephrol; 2023 Jan; 18(1):47-59. PubMed ID: 36526414
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
[TBL] [Abstract][Full Text] [Related]
29. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial.
Jones RB; Hiemstra TF; Ballarin J; Blockmans DE; Brogan P; Bruchfeld A; Cid MC; Dahlsveen K; de Zoysa J; Espigol-Frigolé G; Lanyon P; Peh CA; Tesar V; Vaglio A; Walsh M; Walsh D; Walters G; Harper L; Jayne D;
Ann Rheum Dis; 2019 Mar; 78(3):399-405. PubMed ID: 30612116
[TBL] [Abstract][Full Text] [Related]
30. Immunosuppressive Therapies in Ear, Nose, and Throat Involvement in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Results From a Multicenter Retrospective Cohort Study.
Krol RM; Schaap CM; Welsing PMJ; Klaasen R; Remmelts HHF; Hagen EC; Heijstek MW; Spierings J
J Rheumatol; 2023 Mar; 50(3):384-389. PubMed ID: 36243413
[TBL] [Abstract][Full Text] [Related]
31. Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Wallace ZS; Fu X; Liao K; Kallenberg CGM; Langford CA; Merkel PA; Monach P; Seo P; Specks U; Spiera R; St Clair EW; Zhang Y; Choi H; Stone JH
Arthritis Rheumatol; 2019 Nov; 71(11):1879-1887. PubMed ID: 31162829
[TBL] [Abstract][Full Text] [Related]
32. A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis.
Mohammad AJ; Segelmark M
J Rheumatol; 2014 Jul; 41(7):1366-73. PubMed ID: 24882836
[TBL] [Abstract][Full Text] [Related]
33. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis.
Slot MC; Tervaert JW; Boomsma MM; Stegeman CA
Arthritis Rheum; 2004 Apr; 51(2):269-73. PubMed ID: 15077271
[TBL] [Abstract][Full Text] [Related]
34. Proteinuria and hematuria after remission induction are associated with outcome in ANCA-associated vasculitis.
Benichou N; Charles P; Terrier B; Jones RB; Hiemstra T; Mouthon L; Bajema I; Berden A; Thervet E; Guillevin L; Jayne D; Karras A;
Kidney Int; 2023 Jun; 103(6):1144-1155. PubMed ID: 36940799
[TBL] [Abstract][Full Text] [Related]
35. ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease.
Kemna MJ; Damoiseaux J; Austen J; Winkens B; Peters J; van Paassen P; Cohen Tervaert JW
J Am Soc Nephrol; 2015 Mar; 26(3):537-42. PubMed ID: 25324502
[TBL] [Abstract][Full Text] [Related]
36. Clinical presentation and outcome prediction of clinical, serological, and histopathological classification schemes in ANCA-associated vasculitis with renal involvement.
Córdova-Sánchez BM; Mejía-Vilet JM; Morales-Buenrostro LE; Loyola-Rodríguez G; Uribe-Uribe NO; Correa-Rotter R
Clin Rheumatol; 2016 Jul; 35(7):1805-16. PubMed ID: 26852317
[TBL] [Abstract][Full Text] [Related]
37. Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data.
de Joode AAE; Sanders JSF; Puéchal X; Guillevin LP; Hiemstra TF; Flossmann O; Rasmussen N; Westman K; Jayne DR; Stegeman CA
Rheumatology (Oxford); 2017 Nov; 56(11):1894-1901. PubMed ID: 28977502
[TBL] [Abstract][Full Text] [Related]
38. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.
Karras A; Pagnoux C; Haubitz M; Groot K; Puechal X; Tervaert JWC; Segelmark M; Guillevin L; Jayne D;
Ann Rheum Dis; 2017 Oct; 76(10):1662-1668. PubMed ID: 28546260
[TBL] [Abstract][Full Text] [Related]
39. HLA-DPB1 as a Risk Factor for Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Cohort Study.
Hilhorst M; Arndt F; Joseph Kemna M; Wieczorek S; Donner Y; Wilde B; Thomas Epplen J; van Paassen P; Cohen Tervaert JW
Arthritis Rheumatol; 2016 Jul; 68(7):1721-30. PubMed ID: 26866715
[TBL] [Abstract][Full Text] [Related]
40. The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Cartin-Ceba R; Indrakanti D; Specks U; Stone JH; Hoffman GS; Kallenberg CG; Langford CA; Merkel PA; Spiera RF; Monach PA; St Clair EW; Seo P; Tchao NK; Ytterberg SR; Brunetta PG; Song H; Birmingham D; Rovin BH;
Arthritis Rheumatol; 2017 Jan; 69(1):169-175. PubMed ID: 27482943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
